[Show abstract][Hide abstract] ABSTRACT: The paper is concerned with a case history of a 24-year old man suffering from chronic erythromyelosis with erythrokaryocytic metaplasia of the peripheral lymph nodes, bone marrow, spleen, liver, heart and lungs. The hypereosinophilic syndrome and endocardial fibrosis caused diagnostic difficulties. A short-term effect after injection of the plasma from a patient with erythrocytic aplasia containing antierythroblastic antibodies was obtained, tumor tissue mass reduced. Later on courses of CAMP-therapy were initiated. The progression of disease resulted in the patient's death in 2 years.
No preview · Article · Feb 1987 · Terapevticheskii arkhiv
[Show abstract][Hide abstract] ABSTRACT: Activity of monoclonal antibodies HAE3 and HAE9 specific for human erythroid cells to different leukemic cells is described. These monoclonals do not react with nonerythroid leukemic cells. HAE3 and HAE9 reactivities are similar to those of polyclonal monospecific antibodies against an antigen of erythroblasts--a surface antigenic marker of nucleated red cells and reticulocytes. Monoclonal antibodies HAE3 and HAE9 are proposed to be used in diagnosis of leukemias.
No preview · Article · Feb 1986 · Eksperimentalʹnai͡a onkologii͡a
[Show abstract][Hide abstract] ABSTRACT: The authors describe two women with a history of partial red-cell aplasia of the bone marrow without any remissions for 2 and 3 years, followed by the development of erythromyelosis. The latter lasted from 1 to 2 years, the total illness duration being 4 to 5 years. All the attempts to achieve remissions with the use of splenectomy, mono- and polychemotherapy with a purpose of immunosuppression ended in failure. Partial red-cell aplasia is viewed as preleukemia.
No preview · Article · Feb 1986 · Terapevticheskii arkhiv
[Show abstract][Hide abstract] ABSTRACT: Using polyclonal antibodies to an interspecies antigen of erythroblasts (Ag-Eb) with a molecular weight 69 000 D this antigen was revealed by immunofluorescence on the cells of the peripheral blood of patients with erythroleukemias and, in several cases, in those with undifferentiated leukemias. The possibility was shown of using these antibodies as a diagnostic tool when studying erythroleukemias and acute undifferentiated leukemias.
No preview · Article · Sep 1985 · Biulleten' eksperimental'noĭ biologii i meditsiny
[Show abstract][Hide abstract] ABSTRACT: The authors describe 4 patients with grave aplastic anemia that developed after acute virus hepatitis. In two cases aplasia occurred at the icteric period of hepatitis, in one during convalescence, and in one 5 months after the recovery from hepatitis. The counter electrophoresis technique failed to reveal the Australian antigen in all the 4 cases. Ninety per cent of patients out of over 200 reported cases of aplastic anemia that developed after acute virus hepatitis died. Of the 4 cases followed up by the authors, 3 patients died. One of the female patients was subjected to splenectomy 3 weeks after the occurrence of grave aplasia with fatty bone marrow with a purpose of immunodepression. Splenectomy entailed a considerable decrease in hemorrhagic diathesis. Later on the patient was treated with caprine antilymphocytic globulin. At present the patient is in a state of remission. The problems of the pathogenesis of aplastic anemia following acute virus hepatitis and potentialities of the disease treatment are under discussion.
No preview · Article · Feb 1985 · Terapevticheskii arkhiv
[Show abstract][Hide abstract] ABSTRACT: The authors appraise the efficacy of the treatment of severe aplastic anemia by splenectomy, antilymphocyte globulin and cyclophosphamide. A total of 120 patients were placed under observation. Of these, 103 patients had a severe disease pattern, one hundred and 112 patients with aplastic anemia including 96 with a severe pattern were subjected to splenectomy. Of the 112 splenectomized patients, 78 (69.6%) are alive. Of the 96 patients with severe aplasia, 60 patients (62.5%) are alive. Of 43 deceased patients, 7 had been admitted to the hospital 2-12 days before death and had not been subjected to splenectomy. Three patients died shortly after splenectomy, 8 patients died at the second month after operation. During the first 6 months after operation 20% of the operated patients died, whereupon 10 more per cent of the patients died for 5 months. The patients who survived 10 months may happen to develop a complete or partial remission. Complete remission was attained in 18.8% of the patients, almost complete recovery in 17.7% of the operated, considerable improvement of the estimates was attained in 17.7% of the patients. Antilymphocyte globulin was administered to 23 splenectomized patients. The remission was attained in 6 patients, and 8 more patients improved. If the patients did not respond to the treatment with antilymphocyte globulin, or if they developed relapses, the authors administered cyclophosphamide. Of the 15 patients, 9 responded to the treatment (5 patients improved, remission was attained in 4 patients, 3 of whom are in a state of remission until now). On the 15 patients treated with cyclophosphamide 12 patients have been alive for not less that 2 years.
No preview · Article · Feb 1984 · Terapevticheskii arkhiv